Okarska-Napierała, M; Ludwikowska, KM; Szenborn, L; Dudek, N; Mania, A; Buda, P; Książyk, J; Mazur-Malewska, K; Figlerowicz, M; Szczukocki, M; Kucińska, B; Werner, B; Stopyra, L; Czech, A; Berdej-Szczot, E; Gawlik, A; Opalińska, P; Mazur, A; Januszkiewicz-Lewandowska, D; Niszczota, C; Jackowska, T; Wysocki, J; Mois CoR Study Group; Kuchar, E
Pediatric inflammatory multisystem syndrome (PIMS) is a new entity in children, likely associated with previous coronavirus disease 19 (COVID-19) infection. Most of the reports about PIMS come from countries particularly hit by the COVID-19 pandemic. Our aim was to investigate the nature of inflammatory syndromes in Poland (country with low COVID-19 prevalence) and to perceive the emergence of PIMS in our country. On 25 May 2020, we launched a nationwide survey of inflammatory syndromes in children for retrospective (since 4 March 2020) and prospective data collection. Up to 28 July, 39 reported children met the inclusion criteria. We stratified them according to age (<5 and ≥ 5 years old) and COVID-19 status. The majority of children had clinical and laboratory features of Kawasaki disease, probably non-associated with COVID-19. However, children ≥5 years of age had PIMS characteristics, and nine children had COVID-19 confirmation. This is, to our knowledge, the first report of the PIMS register from a country with a low COVID-19 prevalence, and it proves that PIMS may emerge in any area involved in the COVID-19 pandemic. In a context of limited COVID-19 testing availability, other risk factors of PIMS, e.g., older age, should be considered in the differential diagnosis of inflammatory syndromes in children.